Huang, Dan <br/><br/>
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.  [electronic resource] 

 -  Cancer research  Feb 2010 
 - 1053-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-09-3722  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--pharmacology<br/>Animals<br/>Blotting, Western<br/>Carcinoma, Renal Cell--blood supply<br/>Cell Line<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Endothelial Cells--cytology<br/>Endothelium, Vascular--drug effects<br/>Female<br/>Humans<br/>Indoles--pharmacology<br/>Kidney Neoplasms--blood supply<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Neovascularization, Pathologic--genetics<br/>Pyrroles--pharmacology<br/>RNA Interference<br/>Receptor, Platelet-Derived Growth Factor beta--genetics<br/>Sunitinib<br/>Tumor Burden--drug effects<br/>Vascular Endothelial Growth Factor Receptor-2--genetics<br/>Xenograft Model Antitumor Assays